4519 — Chugai Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- ¥9tn
- ¥8tn
- ¥1tn
- 98
- 24
- 92
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.62 | ||
| PEG Ratio (f) | 5.07 | ||
| EPS Growth (f) | 5.11% | ||
| Dividend Yield (f) | 1.66% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.3 | ||
| Price to Tang. Book | 5.37 | ||
| Price to Free Cashflow | 25.67 | ||
| Price to Sales | 7.75 | ||
| EV to EBITDA | 16.76 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 26.71% | ||
| Return on Equity | 21.34% | ||
| Operating Margin | 39.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 686,184 | 786,946 | 999,759 | 1,259,726 | 1,111,367 | 1,091,937 | 1,139,635 | 13.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +73.49 | +34.15 | +42.77 | +21.87 | -12.2 | +4.1 | +7.52 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Directors
- Tatsuro Kosaka CHM (68)
- Osamu Okuda PRE (58)
- Motoo Ueno VCH (64)
- Toshiaki Itagaki CFO
- Kazuya Usuda FID
- Shinya Unno EVP
- Junichi Ebihara SEO
- Keiji Kono SEO
- Mark Noguchi SEO
- Hisafumi Okabe SEO
- Naofumi Yamada SEO
- Tetsuya Yamaguchi SEO
- Shinji Hidaka DSL
- Yoshiyuki Yano DHR
- Tsukasa Kusano EXO
- Hiroyuki Matsumoto EXO
- Hiroshi Murata EXO
- Junichi Nezu EXO
- Kaori Ohuchi EXO
- Satoko Shisai EXO
- Masatoshi Takada EXO
- Minoru Watanabe EXO
- William Anderson DRC (54)
- Christoph Franz DRC (61)
- James Sabry DRC (62)
- Yoichiro Ichimaru IND (72)
- Mariko Momoi IND (73)
- Masayuki Oku IND (77)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 8th, 1943
- Public Since
- March 3rd, 1956
- No. of Shareholders
- 54,361
- No. of Employees
- 7,604
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 1,645,313,955
- Address
- 15F, Nihonbashi Mitsui Tower, CHUO-KU, 103-8324
- Web
- https://www.chugai-pharm.co.jp/
- Phone
- +81 332816611
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4519
Q1 2024 Chugai Pharmaceutical Co Ltd Earnings Call (Japanese)
Dividend For 4519.T - 41.0000 JPY
Q2 2024 Chugai Pharmaceutical Co Ltd Earnings Release
Q2 2024 Chugai Pharmaceutical Co Ltd Earnings Call (Japanese)
Similar to 4519
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Chugai Pharmaceutical Co share price?
As of Today at 19:05 UTC, shares in Chugai Pharmaceutical Co are trading at ¥5,237. This share price information is delayed by 15 minutes.
How has the Chugai Pharmaceutical Co share price performed this year?
Shares in Chugai Pharmaceutical Co last closed at ¥5,237 and the price had moved by +58.12% over the past 365 days. In terms of relative price strength the Chugai Pharmaceutical Co share price has outperformed the Nikkei 225 Index by +12.88% over the past year.
What are the analyst and broker recommendations for Chugai Pharmaceutical Co?
The overall consensus recommendation for Chugai Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Chugai Pharmaceutical Co dividend yield?
The Chugai Pharmaceutical Co dividend yield is 1.53% based on the trailing twelve month period.
Does Chugai Pharmaceutical Co pay a dividend?
Last year, Chugai Pharmaceutical Co paid a total dividend of ¥80, and it currently has a trailing dividend yield of 1.53%.Looking ahead, shares in Chugai Pharmaceutical Co are due to go ex-dividend on 2024-06-27 and the next dividend pay date is 2024-09-01.
When does Chugai Pharmaceutical Co next pay dividends?
Chugai Pharmaceutical Co are due to go ex-dividend on 2024-06-27 and the next dividend pay date is 2024-09-01. The historic dividend yield on Chugai Pharmaceutical Co shares is currently 1.53%.
How do I buy Chugai Pharmaceutical Co shares?
To buy shares in Chugai Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chugai Pharmaceutical Co?
As of the previous close price of ¥5,237, shares in Chugai Pharmaceutical Co had a market capitalisation of ¥9tn.
Where are Chugai Pharmaceutical Co shares listed?
Here are the trading details for Chugai Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4519
What kind of share is Chugai Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Chugai Pharmaceutical Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chugai Pharmaceutical Co share price forecast for 2024?
The analyst consensus target price for shares in Chugai Pharmaceutical Co is ¥6,178. That is 17.97% above the last closing price of ¥5,237.
Analysts covering Chugai Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥208 for the next financial year.
What is the trend in the Chugai Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chugai Pharmaceutical Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -10.47%.
As of the last closing price of ¥5,237, shares in Chugai Pharmaceutical Co were trading +5.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chugai Pharmaceutical Co PE Ratio?
The Chugai Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 24.62. The shares last closed at ¥5,237.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chugai Pharmaceutical Co?
Chugai Pharmaceutical Co's management team is headed by:
- Tatsuro Kosaka - CHM
- Osamu Okuda - PRE
- Motoo Ueno - VCH
- Toshiaki Itagaki - CFO
- Kazuya Usuda - FID
- Shinya Unno - EVP
- Junichi Ebihara - SEO
- Keiji Kono - SEO
- Mark Noguchi - SEO
- Hisafumi Okabe - SEO
- Naofumi Yamada - SEO
- Tetsuya Yamaguchi - SEO
- Shinji Hidaka - DSL
- Yoshiyuki Yano - DHR
- Tsukasa Kusano - EXO
- Hiroyuki Matsumoto - EXO
- Hiroshi Murata - EXO
- Junichi Nezu - EXO
- Kaori Ohuchi - EXO
- Satoko Shisai - EXO
- Masatoshi Takada - EXO
- Minoru Watanabe - EXO
- William Anderson - DRC
- Christoph Franz - DRC
- James Sabry - DRC
- Yoichiro Ichimaru - IND
- Mariko Momoi - IND
- Masayuki Oku - IND